ValuEngine upgraded shares of Cutera (NASDAQ:CUTR) from a hold rating to a buy rating in a research report released on Thursday.
Several other equities analysts have also issued reports on CUTR. Zacks Investment Research raised shares of Cutera from a sell rating to a hold rating in a report on Tuesday, July 10th. BidaskClub lowered shares of Cutera from a strong-buy rating to a buy rating in a report on Friday, July 27th. Stifel Nicolaus cut their price target on shares of Cutera from $55.00 to $45.00 and set a hold rating on the stock in a report on Wednesday, August 8th. Stephens dropped their price objective on shares of Cutera from $40.00 to $24.94 and set a sell rating on the stock in a report on Friday, October 5th. Finally, Sidoti set a $50.00 price objective on shares of Cutera and gave the company a buy rating in a report on Friday, October 5th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The stock has an average rating of Hold and an average target price of $39.24.
NASDAQ CUTR traded down $0.23 on Thursday, hitting $21.09. The stock had a trading volume of 1,110 shares, compared to its average volume of 259,570. Cutera has a 52-week low of $19.11 and a 52-week high of $56.05. The firm has a market capitalization of $295.00 million, a P/E ratio of 27.51 and a beta of 0.83.
Cutera (NASDAQ:CUTR) last released its quarterly earnings results on Tuesday, August 7th. The medical device company reported $0.12 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.06). Cutera had a return on equity of 10.21% and a net margin of 15.67%. The firm had revenue of $42.55 million during the quarter, compared to analysts’ expectations of $41.50 million. On average, analysts forecast that Cutera will post -0.32 EPS for the current year.
In related news, insider James A. Reinstein acquired 1,000 shares of the company’s stock in a transaction dated Wednesday, August 29th. The shares were purchased at an average cost of $32.02 per share, with a total value of $32,020.00. Following the completion of the acquisition, the insider now directly owns 139,907 shares of the company’s stock, valued at $4,479,822.14. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 1.80% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of the business. Gamco Investors INC. ET AL boosted its holdings in Cutera by 11.7% in the third quarter. Gamco Investors INC. ET AL now owns 660,800 shares of the medical device company’s stock valued at $21,509,000 after purchasing an additional 69,000 shares during the last quarter. Gabelli Funds LLC boosted its holdings in Cutera by 24.7% in the third quarter. Gabelli Funds LLC now owns 509,200 shares of the medical device company’s stock valued at $16,574,000 after purchasing an additional 100,700 shares during the last quarter. Partner Fund Management L.P. boosted its holdings in Cutera by 21.6% in the second quarter. Partner Fund Management L.P. now owns 487,347 shares of the medical device company’s stock valued at $19,640,000 after purchasing an additional 86,621 shares during the last quarter. Teton Advisors Inc. boosted its holdings in Cutera by 7.2% in the third quarter. Teton Advisors Inc. now owns 378,339 shares of the medical device company’s stock valued at $12,315,000 after purchasing an additional 25,543 shares during the last quarter. Finally, Peregrine Capital Management LLC boosted its holdings in Cutera by 0.7% in the third quarter. Peregrine Capital Management LLC now owns 368,758 shares of the medical device company’s stock valued at $12,003,000 after purchasing an additional 2,666 shares during the last quarter. 93.36% of the stock is currently owned by institutional investors.
Cutera Company Profile
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
See Also: Diversification in Investing
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.